ARSYNL Rx review

ARSYNL Rx publishes a one-month injection plan billed monthly: compounded semaglutide with B12 at $219 and tirzepatide at $269. Product pages advertise flat pricing, included medication, injection supplies, consultation and no separate membership fee. They also describe provider review before dose increases and ongoing check-ins. These are the provider’s current service promises rather than a guarantee of future price, a particular prescription or a fixed follow-up schedule for everyone. Confirm which clinical contacts and laboratory services are included before accepting a subscription. The product-specific quote matters more than a general storefront range. The semaglutide cost guide explains why a starting price should be compared with the complete ongoing commitment.

The tirzepatide injection page itself has an ingredient discrepancy. Its title and comparison card use B12, while its detailed description and FAQ use B6. Ask for the prescribed formulation and the pharmacy label rather than assume either additive is correct for your order. A claim that a vitamin supports nutrition or tolerance does not establish that this particular combination improves outcomes. ARSYNL explicitly states that its compounded drugs are not FDA-approved. Brand-drug trials cannot establish the effectiveness, sterility or stability of a different pharmacy preparation. The compounded tirzepatide guide separates those evidence questions from the convenience of an online program.

The other tirzepatide format is HypoSpray, a compounded transdermal spray applied to the skin. Its offer explicitly says billed monthly, while its supply description says one bottle lasts exactly four weeks. Supply duration is not proof of a 28-day charge interval, so the bottle alone does not establish thirteen or fourteen automatic charges. Ask how the program handles replacement supply, renewal dates and any gap between a bottle running out and the next monthly charge. The site also presents injection-equivalent dose language. That is a marketing comparison, not established bioequivalence or a reason to transfer an injected dose to a spray. A non-injection route needs its own absorption and clinical evidence. The tirzepatide evidence review explains why a familiar ingredient does not establish that a different delivery system works.

The care and pharmacy disclosures offer useful names but require reconciliation. Current product pages identify the Arora Health network and name Sean Arora, Shannon Arora and Alex Saucedo in leadership roles. The general FAQ instead identifies MD Integrations and lists particular physician names and license numbers for four states. Those are provider disclosures, not independent current credential checks or confirmation of your assigned clinician. The FAQ names Manifest Pharmacy in Greer, South Carolina, and RX Compounding Store in Miami, Florida, as possible dispensing partners. It allows requesting a local pharmacy, with no guarantee of the same price; terms ask that this request be made before completing the order. Confirm the actual dispensing location and relevant state license. ARSYNL serves adults and describes product-specific state restrictions during intake, without publishing a complete current availability list. It advertises most feedback within 24 hours, with live video or chat when required; that is not a guaranteed response time for every case.

The FAQ says medication is billed when shipped, but its general getting-started description places purchase before the questionnaire. Ask whether any amount is captured earlier and what happens if prescribing is declined; the reviewed policies do not establish a universal full-refund promise. The FAQ describes account cancellation and contact before refills. The return policy permits subscription changes before shipment and says sales are final after payment and carrier handoff, while directing damaged or lost orders to support. Do not interpret cancellation at any time as reversal of a processed charge. Another return-policy sentence says the company does not ship refrigerated products and that transit delays will not affect them. That broad statement is insufficient storage guidance for a compounded GLP-1 injection. Confirm the actual pharmacy’s shipping and storage instructions, and resolve an inadequately refrigerated shipment with the pharmacist before use. The pharmacy-check guide explains how to verify the dispensing relationship and preparation-specific instructions.